Brain tDCS as a disease-modifying treatment of MS: A pilot study in a chronic EAE model

被引：0
|
作者：
Santangelo, R. [1 ]
Castoldi, V. [1 ]
Finardi, A. [1 ]
Cursi, M. [1 ]
Camaleonti, L. [1 ]
Comi, G. [1 ]
Furlan, R. [1 ]
Leocani, L. [1 ]
机构：
[1] Osped San Raffaele, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1102
引用
收藏
页码：569 / 570
页数：2
相关论文
共 50 条
  • [1] Disease-modifying treatment - if and when to stop in relapsing MS
    Kister, I.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 42 - 43
  • [2] Disease-modifying treatment - if and when to stop in progressive MS?
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 43 - 43
  • [3] Highly effective disease-modifying treatment as initial MS therapy
    Schmierer, Klaus
    Sorensen, Per S.
    Baker, David
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (03) : 286 - 294
  • [4] TREATMENT - DISEASE-MODIFYING THERAPIES
    LIEBERMAN, JD
    SCHATTEN, S
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1988, 14 (01) : 223 - 243
  • [5] Use of Disease-Modifying Therapies in Pediatric MS
    Simone, Marta
    Chitnis, Tanuja
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2016, 18 (08)
  • [6] Potential targets for disease-modifying treatments in MS
    Hartung, HP
    JOURNAL OF NEUROLOGY, 2004, 251 : 12 - 16
  • [7] Use of Disease-Modifying Therapies in Pediatric MS
    Marta Simone
    Tanuja Chitnis
    Current Treatment Options in Neurology, 2016, 18
  • [8] TREATMENT PATTERNS AMONG MS PATIENTS NEWLY INITIATING DISEASE-MODIFYING THERAPY
    Kantor, D.
    Mehta, R.
    Pelletier, C.
    Tian, M.
    Noxon, V
    Johnson, B. H.
    Bonafede, M.
    VALUE IN HEALTH, 2019, 22 : S703 - S703
  • [9] Hepatitis E virus infections in patients with MS on oral disease-modifying treatment
    Diebold, Martin
    Fischer-Barnicol, Bettina
    Tsagkas, Charidimos
    Kuhle, Jens
    Kappos, Ludwig
    Derfuss, Tobias
    Decard, Bernhard F.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (05):
  • [10] Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS)
    Stamatellos, Vasileios-Periklis
    Papazisis, Georgios
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2023, 18 (01) : 39 - 50
12345